Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Cancer-testis (CT) antigens are promising immunotherapy targets due to restricted expression in germ cells and tumors.
• Current CT-based immunotherapies primarily target CT-rich cancers like melanoma and lung cancer.

Purpose of the Study:

• To survey CT antigen expression across ten common cancer types using The Cancer Genome Atlas (TCGA) datasets.
• To investigate the specificity and enrichment of CT expression within distinct cancer molecular subtypes.
• To explore the regulatory mechanisms and prognostic value of CT antigens in various cancers.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) datasets to analyze CT antigen gene expression.
• Examined DNA methylation data to understand epigenetic regulation of CT antigens.
• Correlated CT expression with patient outcomes to assess prognostic significance.

Main Results:

• CT antigen expression is specific and enriched in certain cancer molecular subtypes, not uniformly distributed.
• Identified specific CT antigens (e.g., HORMAD1, CXorf61, ACTL8, PRAME) highly enriched in basal breast cancer, magnoid lung adenocarcinoma, and ccB clear cell renal cell carcinoma subtypes.
• Demonstrated that CT antigens are regulated by epigenetic mechanisms and/or tissue- and subtype-specific transcription factors.
• Found that while some CT antigens correlate with patient outcomes, few serve as independent prognostic markers.

Conclusions:

• CT antigens exhibit heterogeneity in activation modes and functions across different cancer types and subtypes.
• The findings support a cancer subtype-oriented approach for applying CT antigens as biomarkers and immunotherapeutic targets.